These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

338 related items for PubMed ID: 16157124

  • 21. Placental histology for targeted risk assessment of recurrent spontaneous preterm birth.
    Suresh S, Freedman A, Adams M, Hirsch E, Ernst LM.
    Am J Obstet Gynecol; 2024 Apr; 230(4):452.e1-452.e11. PubMed ID: 37751829
    [Abstract] [Full Text] [Related]

  • 22. 17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study.
    Nelson DB, McIntire DD, McDonald J, Gard J, Turrichi P, Leveno KJ.
    Am J Obstet Gynecol; 2017 Jun; 216(6):600.e1-600.e9. PubMed ID: 28223163
    [Abstract] [Full Text] [Related]

  • 23. The use of progestational agents for preterm birth: lessons from a mouse model.
    Elovitz MA, Mrinalini C.
    Am J Obstet Gynecol; 2006 Oct; 195(4):1004-10. PubMed ID: 17000233
    [Abstract] [Full Text] [Related]

  • 24. Recurrent preterm birth in women treated with 17 α-hydroxyprogesterone caproate: the contribution of risk factors in the penultimate pregnancy.
    Coleman S, Wallace L, Alexander J, Istwan N.
    J Matern Fetal Neonatal Med; 2012 Jul; 25(7):1034-8. PubMed ID: 21854134
    [Abstract] [Full Text] [Related]

  • 25. Recurrence of spontaneous versus medically indicated preterm birth.
    Ananth CV, Getahun D, Peltier MR, Salihu HM, Vintzileos AM.
    Am J Obstet Gynecol; 2006 Sep; 195(3):643-50. PubMed ID: 16949395
    [Abstract] [Full Text] [Related]

  • 26. Preterm birth prevention by 17 alpha-hydroxyprogesterone caproate vs. daily nursing surveillance.
    Rittenberg C, Newman RB, Istwan NB, Rhea DJ, Stanziano GJ.
    J Reprod Med; 2009 Feb; 54(2):47-52. PubMed ID: 19301566
    [Abstract] [Full Text] [Related]

  • 27. Women receiving 17-alpha-hydroxyprogesterone caproate hospitalized for preterm labor at less than 34 weeks benefit from daily perinatal nursing surveillance.
    Rittenberg C, Sullivan S, Istwan N, Rhea D, Stanziano G, Newman R.
    Am J Obstet Gynecol; 2008 Oct; 199(4):389.e1-4. PubMed ID: 18928983
    [Abstract] [Full Text] [Related]

  • 28. Pregnancy duration with use of 17-α-hydroxyprogesterone caproate in a retrospective cohort at high risk of recurrent preterm birth.
    Massa K, Childress K, Vricella LK, Boerrigter A, Franklin BHK, Sauer M, Armbruster R, Tomlinson T.
    Am J Obstet Gynecol MFM; 2020 Nov; 2(4):100219. PubMed ID: 33345927
    [Abstract] [Full Text] [Related]

  • 29. 17-alphahydroxyprogesterone caproate in women with previous spontaneous preterm delivery: does a previous term delivery affect the rate of recurrence?
    Barton JR, Barton LA, Istwan NB, Rhea DJ, Desch CN, Sibai BM.
    Am J Obstet Gynecol; 2011 Sep; 205(3):269.e1-6. PubMed ID: 22071060
    [Abstract] [Full Text] [Related]

  • 30. 17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial.
    Winer N, Bretelle F, Senat MV, Bohec C, Deruelle P, Perrotin F, Connan L, Vayssière C, Langer B, Capelle M, Azimi S, Porcher R, Rozenberg P, Groupe de Recherche en Obstétrique et Gynécologie.
    Am J Obstet Gynecol; 2015 Apr; 212(4):485.e1-485.e10. PubMed ID: 25448515
    [Abstract] [Full Text] [Related]

  • 31. Impact of 17P usage on NICU admissions in a managed medicaid population--a five-year review.
    Mason MV, Poole-Yaeger A, Krueger CR, House KM, Lucas B.
    Manag Care; 2010 Feb; 19(2):46-52. PubMed ID: 20550052
    [Abstract] [Full Text] [Related]

  • 32. Vaginal micronized progesterone and risk of preterm delivery in high-risk twin pregnancies: secondary analysis of a placebo-controlled randomized trial and meta-analysis.
    Klein K, Rode L, Nicolaides KH, Krampl-Bettelheim E, Tabor A, PREDICT Group.
    Ultrasound Obstet Gynecol; 2011 Sep; 38(3):281-7. PubMed ID: 21739499
    [Abstract] [Full Text] [Related]

  • 33. A prospective masked observational study of uterine contraction frequency in twins.
    Newman RB, Iams JD, Das A, Goldenberg RL, Meis P, Moawad A, Sibai BM, Caritis SN, Miodovnik M, Paul RH, Dombrowski MP, Fischer M, National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units.
    Am J Obstet Gynecol; 2006 Dec; 195(6):1564-70. PubMed ID: 16769014
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Rates of recurrent preterm birth by maternal body habitus in women receiving 17α-hydroxyprogesterone caproate.
    Timofeev J, Feghali M, Boyle A, Istwan N, Rhea D, Driggers RW.
    J Matern Fetal Neonatal Med; 2013 Jun; 26(9):881-4. PubMed ID: 23311766
    [Abstract] [Full Text] [Related]

  • 37. Implications of idiopathic preterm delivery for previous and subsequent pregnancies.
    Kristensen J, Langhoff-Roos J, Kristensen FB.
    Obstet Gynecol; 1995 Nov; 86(5):800-4. PubMed ID: 7566852
    [Abstract] [Full Text] [Related]

  • 38. 17α Hydroxyprogesterone caproate for prevention of recurrent spontaneous preterm birth.
    Merlob P, Stahl B, Klinger G.
    Reprod Toxicol; 2012 Jan; 33(1):15-9. PubMed ID: 22120850
    [Abstract] [Full Text] [Related]

  • 39. The Effect of Prior Term Birth on Risk of Recurrent Spontaneous Preterm Birth.
    Purisch SE, Turitz AL, Elovitz MA, Levine LD.
    Am J Perinatol; 2018 Mar; 35(4):380-384. PubMed ID: 29078234
    [Abstract] [Full Text] [Related]

  • 40. A randomised controlled trial of metronidazole for the prevention of preterm birth in women positive for cervicovaginal fetal fibronectin: the PREMET Study.
    Shennan A, Crawshaw S, Briley A, Hawken J, Seed P, Jones G, Poston L.
    BJOG; 2006 Jan; 113(1):65-74. PubMed ID: 16398774
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.